Positive clinical results set stage for Japan apomorphine filing
This article was originally published in Scrip
Kyowa Hakko Kirin is moving ahead with preparations for a Japanese approval filing for apomorphine (KW-6500) for the treatment of Parkinson's disease, following positive results from a Phase III clinical trial.
You may also be interested in...
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.